The improvement in supportive care and the introduction of new therapeutic agents, including lenalidomide and hypomethylating agents, in myelodysplastic syndromes have improved patients’ outcomes; however, at the same time, the frequency and epidemiology of infections have changed. Therefore, the great strides in the indications and use of new treatment strategies for myelodysplastic syndromes need a parallel progress in the best approach to prophylaxis and supportive therapy for infections. Based on the recognition that the above issues represent an unmet clinical need in myelodysplastic syndromes, an Italian expert panel performed a review of the literature and composed a framework of the best recommendations for optimal infection control in patient candidates to receive active treatment for myelodysplastic syndromes. In this consensus document we report the outcomes of that review and of the consensus meetings held during 2017. The issues tackled in the project dealt with: information to be collected from candidates for active treatment for myelodysplastic syndromes; how to monitor the risk of infection; antimicrobial prophylaxis; the role of iron chelation and antiviral/antibacterial vaccinations. For each of these issues, practice recommendations are provided.

Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: Expert panel consensus-based recommendations / Girmenia, C.; Candoni, A.; Delia, M.; Latagliata, R.; Molteni, A.; Oliva, E. N.; Palumbo, G. A.; Poloni, A.; Salutari, P.; Santini, V.; Voso, M. T.; Musto, P.. - In: BLOOD REVIEWS. - ISSN 0268-960X. - 34:(2019), pp. 16-25. [10.1016/j.blre.2018.10.002]

Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: Expert panel consensus-based recommendations

Candoni A.;
2019-01-01

Abstract

The improvement in supportive care and the introduction of new therapeutic agents, including lenalidomide and hypomethylating agents, in myelodysplastic syndromes have improved patients’ outcomes; however, at the same time, the frequency and epidemiology of infections have changed. Therefore, the great strides in the indications and use of new treatment strategies for myelodysplastic syndromes need a parallel progress in the best approach to prophylaxis and supportive therapy for infections. Based on the recognition that the above issues represent an unmet clinical need in myelodysplastic syndromes, an Italian expert panel performed a review of the literature and composed a framework of the best recommendations for optimal infection control in patient candidates to receive active treatment for myelodysplastic syndromes. In this consensus document we report the outcomes of that review and of the consensus meetings held during 2017. The issues tackled in the project dealt with: information to be collected from candidates for active treatment for myelodysplastic syndromes; how to monitor the risk of infection; antimicrobial prophylaxis; the role of iron chelation and antiviral/antibacterial vaccinations. For each of these issues, practice recommendations are provided.
34
16
25
Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: Expert panel consensus-based recommendations / Girmenia, C.; Candoni, A.; Delia, M.; Latagliata, R.; Molteni, A.; Oliva, E. N.; Palumbo, G. A.; Poloni, A.; Salutari, P.; Santini, V.; Voso, M. T.; Musto, P.. - In: BLOOD REVIEWS. - ISSN 0268-960X. - 34:(2019), pp. 16-25. [10.1016/j.blre.2018.10.002]
Girmenia, C.; Candoni, A.; Delia, M.; Latagliata, R.; Molteni, A.; Oliva, E. N.; Palumbo, G. A.; Poloni, A.; Salutari, P.; Santini, V.; Voso, M. T.; Musto, P.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1294010
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 15
  • ???jsp.display-item.citation.isi??? 15
social impact